AU2019383019A1 - GDF15 analogs and methods for use in decreasing body weight and/or reducing food intake - Google Patents

GDF15 analogs and methods for use in decreasing body weight and/or reducing food intake Download PDF

Info

Publication number
AU2019383019A1
AU2019383019A1 AU2019383019A AU2019383019A AU2019383019A1 AU 2019383019 A1 AU2019383019 A1 AU 2019383019A1 AU 2019383019 A AU2019383019 A AU 2019383019A AU 2019383019 A AU2019383019 A AU 2019383019A AU 2019383019 A1 AU2019383019 A1 AU 2019383019A1
Authority
AU
Australia
Prior art keywords
dose
administered
study
fusion protein
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019383019A
Other languages
English (en)
Inventor
Elisa FABBRINI
Robert Hermann
Holly KIMKO
Paul ROTHENBERG
Vedrana Stojanovic-Susulic
Songmao ZHENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2019383019A1 publication Critical patent/AU2019383019A1/en
Priority to AU2025202337A priority Critical patent/AU2025202337A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2019383019A 2018-11-20 2019-11-19 GDF15 analogs and methods for use in decreasing body weight and/or reducing food intake Abandoned AU2019383019A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025202337A AU2025202337A1 (en) 2018-11-20 2025-04-02 GDF15 analogs and methods for use in decreasing body weight and/or reducing food intake

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769675P 2018-11-20 2018-11-20
US62/769,675 2018-11-20
PCT/IB2019/059945 WO2020104948A1 (en) 2018-11-20 2019-11-19 Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025202337A Division AU2025202337A1 (en) 2018-11-20 2025-04-02 GDF15 analogs and methods for use in decreasing body weight and/or reducing food intake

Publications (1)

Publication Number Publication Date
AU2019383019A1 true AU2019383019A1 (en) 2021-06-03

Family

ID=70773869

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019383019A Abandoned AU2019383019A1 (en) 2018-11-20 2019-11-19 GDF15 analogs and methods for use in decreasing body weight and/or reducing food intake
AU2025202337A Pending AU2025202337A1 (en) 2018-11-20 2025-04-02 GDF15 analogs and methods for use in decreasing body weight and/or reducing food intake

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025202337A Pending AU2025202337A1 (en) 2018-11-20 2025-04-02 GDF15 analogs and methods for use in decreasing body weight and/or reducing food intake

Country Status (15)

Country Link
US (2) US20220315633A1 (enExample)
EP (1) EP3883960A4 (enExample)
JP (2) JP2022513098A (enExample)
KR (1) KR20210094584A (enExample)
CN (2) CN113474363A (enExample)
AU (2) AU2019383019A1 (enExample)
BR (1) BR112021009225A2 (enExample)
CA (1) CA3120236A1 (enExample)
EA (1) EA202191424A1 (enExample)
IL (1) IL283189A (enExample)
JO (1) JOP20210111A1 (enExample)
MX (1) MX2021005908A (enExample)
PH (1) PH12021551119A1 (enExample)
SG (1) SG11202104952PA (enExample)
WO (1) WO2020104948A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY205905A (en) 2018-10-22 2024-11-20 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
ES3061099T3 (en) 2019-10-04 2026-03-31 Amgen Inc Use of gdf15 for treating cardiometabolic syndrome and other conditions
IL310535A (en) * 2021-08-10 2024-03-01 Byomass Inc Anti-gdf15 antibodies, compositions and uses thereof
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9131966B2 (en) * 2013-03-11 2015-09-15 DePuy Synthes Products, Inc. Vertebral manipulation assembly
EP3157947A1 (en) * 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US20190000923A1 (en) * 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
MY205905A (en) * 2018-10-22 2024-11-20 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof

Also Published As

Publication number Publication date
EP3883960A1 (en) 2021-09-29
MX2021005908A (es) 2021-09-08
EA202191424A1 (ru) 2021-08-24
JP2025081388A (ja) 2025-05-27
JP2022513098A (ja) 2022-02-07
US20260159562A1 (en) 2026-06-11
PH12021551119A1 (en) 2021-11-22
US20220315633A1 (en) 2022-10-06
AU2025202337A1 (en) 2025-04-24
JOP20210111A1 (ar) 2021-05-19
KR20210094584A (ko) 2021-07-29
EP3883960A4 (en) 2022-11-09
CN113474363A (zh) 2021-10-01
WO2020104948A1 (en) 2020-05-28
IL283189A (en) 2021-06-30
SG11202104952PA (en) 2021-06-29
CA3120236A1 (en) 2020-05-28
BR112021009225A2 (pt) 2021-10-05
CN121818901A (zh) 2026-04-10

Similar Documents

Publication Publication Date Title
Kommu et al. Semaglutide
JP2025081388A (ja) 体重減少及び／又は食物摂取量低減に使用するためのｇｄｆ１５類似体及び方法
CN113272326B (zh) 治疗嗜中性病症的方法
TW201201832A (en) Pharmaceutical composition comprising AVE0010 and insulin glargine
CN122031677A (zh) 用于治疗代谢功能障碍或低瘦蛋白血症的瘦蛋白受体激动剂抗体
Briere et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept
US9814761B2 (en) Compositions, methods and assays comprising amylin or amlyin analogs for abeta-peptide mediated disorders
EP4408455A1 (en) Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome
CN101460170A (zh) 促生长素抑制素类似物同多巴胺或同促生长素受体拮抗物的组合
US20240390464A1 (en) Treatment of Adults With Overweight or Obesity With or Without Weight-Related Comorbidities
KR20220021890A (ko) 삼중 활성체 지속형 결합체를 유효성분으로 포함하는 약학 조성물
WO2023245543A1 (en) Uses of fgf21 fusion proteins
JP2023544832A (ja) １型糖尿病の治療および予防のための方法および組成物
US20250057829A1 (en) Inhibitors of trpc6 for treating focal segmental glomerulosclerosis
US20230012936A1 (en) Combination therapy using glucagon and glp-1 co-agonists for the treatment of obesity
Moretz Orphan Drug Evaluation: Myalept®(metreleptin) subcutaneous injection
WO2019032469A1 (en) TREATMENT OF OVERWEIGHT AND OBESITY ASSOCIATED WITH LEPTIN IMPAIRMENT
WO2026104987A1 (en) Remibrutinib for use in the treatment of myasthenia gravis
TW202140061A (zh) 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑
EP4017870A1 (en) Compositions and methods for treating and preventing autoimmune induced cardiac long qt syndrome

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted